Pieris Pharmaceuticals (NASDAQ:PIRS) received a $9.00 price objective from HC Wainwright in a research note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 43.77% from the stock’s previous close.

Separately, ValuEngine cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $9.00.

Pieris Pharmaceuticals (NASDAQ PIRS) opened at $6.26 on Wednesday. Pieris Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $6.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The company’s revenue was up 400.3% compared to the same quarter last year. analysts anticipate that Pieris Pharmaceuticals will post -0.72 earnings per share for the current year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.05% of the company’s stock.

A number of hedge funds have recently modified their holdings of PIRS. Voya Investment Management LLC purchased a new position in Pieris Pharmaceuticals in the 2nd quarter valued at approximately $100,000. Wells Fargo & Company MN acquired a new stake in shares of Pieris Pharmaceuticals in the 3rd quarter valued at $105,000. State of Wisconsin Investment Board acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $132,000. The Manufacturers Life Insurance Company raised its holdings in shares of Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 29,150 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at $184,000. 50.45% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Pieris Pharmaceuticals (PIRS) PT Set at $9.00 by HC Wainwright” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/22/pieris-pharmaceuticals-pirs-pt-set-at-9-00-by-hc-wainwright.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Stock Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related stocks with our FREE daily email newsletter.